Page last updated: 2024-11-07

carbachol and Amyotrophic Lateral Sclerosis

carbachol has been researched along with Amyotrophic Lateral Sclerosis in 1 studies

Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.

Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vermeiren, C1
Hemptinne, I1
Vanhoutte, N1
Tilleux, S1
Maloteaux, JM1
Hermans, E1

Other Studies

1 other study available for carbachol and Amyotrophic Lateral Sclerosis

ArticleYear
Loss of metabotropic glutamate receptor-mediated regulation of glutamate transport in chemically activated astrocytes in a rat model of amyotrophic lateral sclerosis.
    Journal of neurochemistry, 2006, Volume: 96, Issue:3

    Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Aspartic Acid; Astrocytes; Bl

2006